Get the Stockscreener App
38.51
1.72%
0.65
Pre-market:
38.51
Cogent Biosciences Inc stock is traded at $38.51, with a volume of 2.46M.
It is up +1.72% in the last 24 hours and down -0.95% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$37.86
Open:
$37.89
24h Volume:
2.46M
Relative Volume:
0.75
Market Cap:
$5.91B
Revenue:
-
Net Income/Loss:
$-284.08M
P/E Ratio:
-15.89
EPS:
-2.4234
Net Cash Flow:
$-234.65M
1W Performance:
-3.48%
1M Performance:
-0.95%
6M Performance:
+219.06%
1Y Performance:
+354.66%
1-Day Range:
$37.71
$39.65
1-Week Range:
$36.01
$40.40
52-Week Range:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
38.51 | 5.81B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Cogent Biosciences announcse U.S. BTD for bezuclastinib - Yahoo Finance
Cogent Biosciences Gains Breakthrough Therapy Designation For Bezuclastinib Combination In GIST - Nasdaq
(COGT) Risk Channels and Responsive Allocation - Stock Traders Daily
Cogent Biosciences stock rises after FDA grants breakthrough therapy status By Investing.com - Investing.com UK
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag - Benzinga
Cogent Biosciences (COGT) Gains FDA Breakthrough Therapy Designa - GuruFocus
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) - The Manila Times
New GIST combo cuts progression risk by 50% in Cogent trial - Stock Titan
Retail Surge: What is the long term forecast for Cogent Biosciences Inc stockJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Real-Time FDA Review Of Bezuclastinib Combo In GIST Might Change The Case For Investing In Cogent Biosciences (COGT) - Sahm
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial - TipRanks
Emerald Mutual Fund Advisers Trust Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Director Fairmount Funds Management Llc Sells 3,500,000 Shares - MarketBeat
Fairmount funds sells Cogent Biosciences (COGT) shares worth $127.4 million - Investing.com Canada
Emerald Advisers LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib ComboHas The Bull Case Changed? - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for Cogent Biosciences (C - GuruFocus
Cogent Biosciences Initiates New Drug Application Submission for Bezuclastinib Under Real-Time Oncology Review - marketscreener.com
FDA Greenlights Cogent Biosciences' New Drug Application for GIS - GuruFocus
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) - The Manila Times
Cancer drug combo cuts GIST progression risk by 50% in key trial - Stock Titan
Campbell & CO Investment Adviser LLC Purchases Shares of 61,634 Cogent Biosciences, Inc. $COGT - MarketBeat
What makes Cogent Biosciences Inc. stock attractive todayQuarterly Profit Review & Expert Verified Movement Alerts - bollywoodhelpline.com
HC Wainwright is bullish on Cogent Biosciences, Inc. (COGT) - MSN
Geopolitics Watch: What are Cogent Biosciences Incs recent SEC filings showingShort Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy - Sahm
(COGT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - Sahm
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next - TechStock²
Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1%Still a Buy? - MarketBeat
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio - Investing News Network
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - MSN
Cogent Biosciences Announces Anticipated 2026 Commercial - GlobeNewswire
Cancer drug maker lays out 2026 plans for new treatments and trials - Stock Titan
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) - Finviz
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge - The Motley Fool
Cogent Biosciences announces proposed concurrent public offerings - MSN
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Cogent Biosciences Inc. stock a buy for dividend growthDurability and Wear Notes & lightweight options for faster days - ulpravda.ru
Cogent Biosciences, Inc. (COGT) Stock Analysis: Unlocking A 41% Upside Potential - DirectorsTalk Interviews
Cogent Bio surges after late-stage trial data for lead drug - MSN
A Look At Cogent Biosciences (COGT) Valuation After Positive Bezuclastinib NDA Filing - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Stock Rating Upgraded by UBS Group - MarketBeat
Aug Ideas: Is Cogent Biosciences Inc. stock a buy for dividend growth2025 Macro Impact & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Will Cogent Biosciences Inc. stock split again soon2025 Volume Leaders & Reliable Price Breakout Signals - ulpravda.ru
Will Cogent Biosciences Inc. stock deliver long term returnsWeekly Profit Summary & Community Consensus Trade Signals - ulpravda.ru
Why Cogent Biosciences Inc. stock is in analyst buy zone2025 EndofYear Setup & Free Technical Confirmation Trade Alerts - ulpravda.ru
Will Cogent Biosciences Inc. stock outperform growth indexesQuarterly Growth Report & Precise Entry and Exit Recommendations - Улправда
How Cogent Biosciences Inc. stock performs during Fed tightening cyclesMarket Movers & Safe Entry Point Identification - ulpravda.ru
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):